Sterling Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Sterling Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.21M	Sell	9,690 -4,037	-29%	-$1.02M	0.04%	304
2026 Q2	$3.66M	Sell	13,727 -1,202	-8%	-$281K	0.06%	240
2026 Q1	$3.41M	Sell	14,929 -9,880	-40%	-$2.21M	0.06%	231
2025 Q4	$5.29M	Buy	24,809 +25	+0.1%	+$5.16K	0.09%	188
2025 Q3	$4.93M	Sell	24,784 -29,725	-55%	-$5.54M	0.07%	190
2025 Q2	$9.41M	Buy	54,509 +3,432	+7%	+$559K	0.13%	104
2025 Q1	$7.96M	Sell	51,077 -5,773	-10%	-$825K	0.12%	104
2024 Q4	$7.83M	Buy	56,850 +9,065	+19%	+$1.19M	0.11%	120
2024 Q3	$7.13M	Buy	+47,785	New	+$6.45M	0.09%	148
2019 Q3	$5.84M	Buy	60,580 +5,830	+11%	+$650K	0.06%	228
2019 Q2	$6.3M	Buy	54,750 +12,790	+30%	+$1.53M	0.06%	228
2019 Q1	$4.94M	Buy	+41,960	New	+$3.67M	0.05%	244
2015 Q2	–	Sell	-19,452	Closed	-$337K	–	879
2015 Q1	$337K	Buy	+19,452	New	+$354K	﹤0.01%	768

Other funds holding ASND

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Sterling Capital Management's ASND Position: Q3 2026 in Review

Sterling Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 29% in Q3 2026, selling an estimated $1.02M and leaving 9,690 shares worth $2.21M. The position accounts for 0.04% of the portfolio, ranked #304.

Sterling Capital Management first reported a position in ASND in Q1 2015 and has held it in 13 quarters since. The position peaked at $9.41M in Q2 2025. 252 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

Sterling Capital Management held 9,690 shares of Ascendis Pharma A/S worth $2.21M as of Q3 2026.
Sterling Capital Management sold 4,037 Ascendis Pharma A/S shares in Q3 2026, an estimated $1.02M.
Ascendis Pharma A/S made up 0.04% of Sterling Capital Management's portfolio in Q3 2026, its #304 holding.
Sterling Capital Management first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 13 quarters since.
Sterling Capital Management's Ascendis Pharma A/S position peaked at $9.41M in Q2 2025.
252 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.